REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John A. Orwin, president and chief executive officer, will present at the Stifel Healthcare Conference on November, 19, 2014 at 8:00 a.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at www.relypsa.com.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval to market Patiromer for Oral Suspension for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood. Relypsa has global royalty-free commercialization rights to Patiromer for Oral Suspension, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.